NCT03050554View on ClinicalTrials.gov

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

October 7, 2019

Study Completion Date

October 7, 2019

Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
DRUG

Avelumab

Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

RADIATION

SBRT

SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Trial Locations (2)

57104

Sanford Health, Sioux Falls

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Andrew Sharabi

OTHER

NCT03050554 - SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter